PhRMA Wants US-UK Trade Deal To Cover Regulatory Alignment
Executive Summary
PhRMA says a UK-US post-Brexit trade agreement should cover good practices in the areas of manufacturing and clinical trials, and wants aligned regulatory approaches to drug development.